Division of Cardiovascular Medicine, Harrington-McLaughlin Heart and Vascular Institute, University Hospitals, Case Western Reserve University, Cleveland, OH 44106-5038, USA.
Transl Res. 2010 Sep;156(3):112-29. doi: 10.1016/j.trsl.2010.06.008.
Cardiovascular disease is the leading cause of death and disability in the Western world. In addition to the advancement of current therapeutic approaches to reduce the associated morbidity and mortality, regenerative medicine and cell-based therapy have been areas of continuous investigation. Circulating and bone-marrow-derived stem or endothelial progenitor cells are an attractive source for regenerative therapy in the cardiovascular field. In this review, we highlight the advantages and limitations of this approach with a focus on key observations from animal studies and clinical trials.
心血管疾病是西方世界致死和致残的主要原因。除了推进当前治疗方法以降低相关发病率和死亡率外，再生医学和基于细胞的治疗一直是持续研究的领域。循环和骨髓来源的干细胞或内皮祖细胞是心血管领域再生治疗的有吸引力的来源。在这篇综述中，我们重点介绍了这种方法的优点和局限性，并强调了来自动物研究和临床试验的关键观察结果。
